Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Manja Meggendorfer, PhD, Wencke Walter, PhD, Stephan Hutter, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 3360.

https://doi.org/10.1182/blood-2019-126580

Published: 2019

Journal Articles

Personalized Ubiquitination Signatures for Predicting Response to Proteasome Inhibitor-Based Therapy of MM Patients

Haim Tsubery, PhD, Lerman Gali, PhD, Kronenfeld Gali, MSc, Itamar Sela, PhD, Yifat Merbl, PhD, Ayelet Itzhaki-Alfia, PhD, Svetlana Trestman, MD, Yael C Cohen, MD, Irit Avivi, MD

Blood (2019) 134 (Supplement_1): 3371.

https://doi.org/10.1182/blood-2019-125274

Published: 2019

Journal Articles

Addressing Challenges in Chronic Lymphocytic Leukemia with Continuing Education: Impact on Practice Behaviors and Knowledge

Anne C Roc, PhD, Julie M. Vose, MD MBA, Susan M. O'Brien, MD, Wendy Turell, DrPH

Blood (2018) 132 (Supplement 1): 5851.

https://doi.org/10.1182/blood-2018-99-120174

Published: 2018

Journal Articles

Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine

David Melnekoff, BS, MSc, Alessandro Lagana, PhD, Wissam Hamou, PhD, Kimaada Allette, BS, Itai Beno, PhD, Violetta Leshchenko, PhD, Deepak Perumal, PhD, Deepu Madduri, MD, Ajai Chari, MD, Hearn Jay Cho, MD PhD, Bart Barlogie, MD PhD, Sundar Jagannath, MD, Joel Dudley, PhD, Robert Sebra, PhD, Samir Parekh, MD

Blood (2017) 130 (Supplement 1): 62.

https://doi.org/10.1182/blood.V130.Suppl_1.62.62

Published: 2017

Journal Articles

Plasma-Derived 3D Culture for Leukemic Proliferation

Pilar De La Puente, PhD M.Sc, Ryan Soo Hoo, Michael P Rettig, PhD, Noha Nabil Salama, PhD, John F DiPersio, MD PhD, Abdel Kareem Azab, PhD

Blood (2017) 130 (Supplement 1): 3831.

https://doi.org/10.1182/blood.V130.Suppl_1.3831.3831

Published: 2017

Journal Articles

Clonal Evolution in CLL

Simon Bouzy, Marine Armand, Clementine Gabillaud, Elise Chapiro, Nadia Bougacha, Fotini Kostopoulou, PhD, Frederic Davi, MD PhD, Magali Le Garff-Tavernier, Karim Maloum, Veronique Leblond, Veronique Morel, Damien Roos-Weil, Anne Lavaud, Jean Gabarre, Choquet Sylvain, Santos Susin, Olivier Bernard, Florence Nguyen-Khac, MD PhD

Blood (2017) 130 (Supplement 1): 3008.

https://doi.org/10.1182/blood.V130.Suppl_1.3008.3008

Published: 2017

Journal Articles

Whole Genome Sequencing in Combination with Transcriptome Sequencing Unravels the Pathogenetic Impact of Rare Balanced Rearrangements in Myeloid Malignancies and May Lead to Novel Personalized Therapeutic Strategies

Claudia Haferlach, MD, Niroshan Nadarajah, Wencke Walter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2017) 130 (Supplement 1): 2673.

https://doi.org/10.1182/blood.V130.Suppl_1.2673.2673

Published: 2017

Journal Articles

Personalized medicine in thrombosis: back to the future

Srikanth Nagalla, Paul F. Bray

Blood (2016) 127 (22): 2665–2671.

https://doi.org/10.1182/blood-2015-11-634832

Published: 2016

Journal Articles

Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

Blood (2015) 126 (23): 2636.

https://doi.org/10.1182/blood.V126.23.2636.2636

Published: 2015

Journal Articles

High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

Pau Montesinos, MD, Joan Ballesteros, David Martínez-Cuadrón, Joaquín Martínez-López, Josefina Serrano, Jaime Perez de Oteyza, Pascual Fernández, Gabriela Rodriguez-Macías, Mª Belén Vidriales, Pilar Herrera, MD PhD, Mar Tormo, MD PhD, Juan Bergua, Raimundo García, MD, Susana Vives, Mª Ángeles Fernández, Esperanza Lavilla, MD, Santiago Jimenez, Jose Antonio Pérez-Simón, Adriana Simiele, Ataulfo González, Bernardo J. González, Carmen Burgaleta, Juan Antonio López, Concepción Bethancourt, Guiomar Bautista, Arancha Alonso, Mercedes Colorado, Jordi Sierra, Begoña Navas, José Angel Hernández-Rivas, Juan Antonio Vera, Mª Lourdes Amador, Raúl Cordoba, MD, Adolfo de la Fuente, Fernando Ramos, MD PhD MPH, Carlos Javier Cerveró, Consolación Rayón, Olga Salamero, Edelmira Martí, Aurelio López, Teresa Olavé, Marta Gaspar, Julian Gorrochategui, José Luis Rojas, Cristina Gomez, Pilar Hernández, Alicia Robles, Ignacio Ortega, Jesús Villoria, Federico Moscardó, Iñaki Troconiz, Miguel A. Sanz, MD PhD

Blood (2015) 126 (23): 4837.

https://doi.org/10.1182/blood.V126.23.4837.4837

Published: 2015

Journal Articles

Pharmacogenocis of PAR4: PAR4 Polymorphism Determines Platelet Response in the Presence of Dual Anti-Platelet Therapy

Benjamin Tourdot, PhD, Paul F. Bray, MD, Leonard C. Edelstein, PhD, Michael Holinstat, PhD FAHA

Blood (2015) 126 (23): 3446.

https://doi.org/10.1182/blood.V126.23.3446.3446

Published: 2015

Journal Articles

Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine

Rachel Gerstein, PhD, Zheng Zhou, MD PhD, Hong Zhang, PhD, Andrew Evens, DO, MSc, FACP, Nicole Walsh, PhD, Leonard Shultz, Rita Bortell, PhD, Michael Brehm, PhD, Jan Cerny, MD PhD, Giles Whalen, MD, Jack Leonard, PhD, Bruce Woda, MD, Dale Greiner, PhD, Alan G. Rosmarin, MD

Blood (2015) 126 (23): 5408.

https://doi.org/10.1182/blood.V126.23.5408.5408

Published: 2015

Journal Articles

Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression

Blood (2014) 124 (21): 722.

https://doi.org/10.1182/blood.V124.21.722.722

Published: 2014

Journal Articles

Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols

Blood (2013) 122 (21): 1294.

https://doi.org/10.1182/blood.V122.21.1294.1294

Published: 2013

Journal Articles

Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine

Blood (2013) 122 (21): 1347.

https://doi.org/10.1182/blood.V122.21.1347.1347

Published: 2013

Journal Articles

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

Blood (2013) 122 (21): 482.

https://doi.org/10.1182/blood.V122.21.482.482

Published: 2013

Journal Articles

Combined targeted and immunotherapy: the future of personalized medicine

Aurélien Marabelle, Christophe Caux

Blood (2012) 120 (23): 4454–4455.

https://doi.org/10.1182/blood-2012-09-455105

Published: 2012

Journal Articles

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

Costa Bachas, Gerrit Jan Schuurhuis, Iris H. I. M. Hollink, Zinia J. Kwidama, Bianca F. Goemans, C. Michel Zwaan, Marry M. van den Heuvel-Eibrink, Eveline S. J. M. de Bont, Dirk Reinhardt, Ursula Creutzig, Valerie de Haas, Yehuda G. Assaraf, Gertjan J. L. Kaspers, Jacqueline Cloos

Blood (2010) 116 (15): 2752–2758.

https://doi.org/10.1182/blood-2010-03-276519

Published: 2010

Includes: Supplemental data

Journal Articles

Personalized medicine for AML?

Franklin O. Smith

Blood (2010) 116 (15): 2622–2623.

https://doi.org/10.1182/blood-2010-07-296418

Published: 2010

Journal Articles

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

Blood (2009) 114 (22): 2655.

https://doi.org/10.1182/blood.V114.22.2655.2655

Published: 2009

NARROW

Genome Data Allow in silico Pharmacogenetic Studies Using the Genetic Makeup of Both the Individual Patient As Well As the Disease

Personalized Ubiquitination Signatures for Predicting Response to Proteasome Inhibitor-Based Therapy of MM Patients

Addressing Challenges in Chronic Lymphocytic Leukemia with Continuing Education: Impact on Practice Behaviors and Knowledge

Single-Cell RNA Sequencing Reveals Distinct Transcriptomic Profiles of Multiple Myeloma with Implications for Personalized Medicine

Plasma-Derived 3D Culture for Leukemic Proliferation

Clonal Evolution in CLL

Whole Genome Sequencing in Combination with Transcriptome Sequencing Unravels the Pathogenetic Impact of Rare Balanced Rearrangements in Myeloid Malignancies and May Lead to Novel Personalized Therapeutic Strategies

Personalized medicine in thrombosis: back to the future

Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG AHOD0031) Comparative Analysis

High Correlation Clinical Responses to 1 st Line Acute Myeloid Leukemia Treatment with an Ex Vivo Native Environment Precision Medicine Test

Pharmacogenocis of PAR4: PAR4 Polymorphism Determines Platelet Response in the Presence of Dual Anti-Platelet Therapy

Patient-Derived Xenografts (PDX) of B Cell Lymphoma in NSG Mice: A Mouse Avatar for Developing Personalized Medicine

Interim Analysis of the Mmrf Commpass Trial: Identification of Novel Rearrangements Potentially Associated with Disease Initiation and Progression

Personalizing Therapies With Ex Vivo Pharmacological Responses May Uncover The Differences Between IDA-DNR-MIT Among European AML Protocols

Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine

Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling

Combined targeted and immunotherapy: the future of personalized medicine

High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine

Personalized medicine for AML?

Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only